EduBourseActualitésQuantum Genomics granted two new U.S. patents covering lead product QGC001

Quantum Genomics granted two new U.S. patents covering lead product QGC001

Dernière mise à jour: octobre 21, 2021

Patents protect asset until 2031 and 2033

Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that the United States Patent and Trademark Office (USPTO) issued two U.S. Patents (No. 9,340,497 and No. 9,278,921) pertaining to the Company’s lead investigational drug candidate, QGC001, a first-in-class Brain Aminopeptidase A Inhibitor (BAPAI).

The claims of the first granted patent (No. 9,340,497) cover the crystalline trihydrate form of QGC001, which is currently being evaluated in a Phase 2 trial for the treatment of hypertension. To date, related applications have been granted in China, Japan, Israel, New Zealand, Mexico, the Russian Federation and South Africa. Patent applications for similar claims are pending in Europe and in many other countries, including Brazil, Canada, South Korea and India. The patent is valid through November 2031, and could be extended by up to five 2023s under the Drug Price Competition and Patent Term Restoration Act, depending on the approval of a new drug application (NDA).

The second patent (No. 9,278,921) issued by the USPTO claims a new crystalline phase of QGC001 with L-lysine and its use for the treatment of hypertension and heart failure. This patent is valid through October 2033, and its expiration date could also be extended by up to five 2023s.

Lionel Segard, Quantum Genomics’ President and Chief Executive Officer, commented, “We are pleased that the USPTO has issued these two patents for our lead candidate, QGC001. They are important additions to our intellectual property portfolio. These patents further strengthen the protection of QGC001 and its use for the treatment of hypertension and heart failure in one of our major markets, potentially until 2038.”

Pierre Perrin-Monlouis
Pierre Perrin-Monlouis
Fondateur de Rente et Patrimoine (cabinet de gestion de patrimoine), Pierre Perrin-Monlouis est un analyste et trader pour compte propre. Il vous fait profiter de son expérience en trading grâce à ses analyses financières et décrypte pour vous les actualités des marchés. Son approche globale des marchés combine à la fois l'analyse technique et l'analyse fondamentale sur l'ensemble des marchés : crypto, forex, actions et matières premières.
ARTICLES SIMILAIRES